Morgan Stanley Boosts IQVIA (NYSE:IQV) Price Target to $250.00

IQVIA (NYSE:IQV - Free Report) had its target price lifted by Morgan Stanley from $245.00 to $250.00 in a research note published on Tuesday,Benzinga reports. Morgan Stanley currently has an overweight rating on the medical research company's stock.

Other equities analysts also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft cut their price target on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Bank of America cut their price target on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a report on Friday, December 13th. The Goldman Sachs Group cut their price target on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Truist Financial reaffirmed a "buy" rating and set a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a research note on Monday. Finally, TD Cowen dropped their price objective on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $251.67.

IQVIA Stock Performance

Shares of IQVIA stock traded down $2.40 during midday trading on Tuesday, hitting $193.65. The company had a trading volume of 679,339 shares, compared to its average volume of 1,364,403. The stock has a market cap of $35.15 billion, a price-to-earnings ratio of 25.82, a PEG ratio of 2.25 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a fifty day simple moving average of $200.59 and a 200 day simple moving average of $218.51. IQVIA has a 12-month low of $187.62 and a 12-month high of $261.73.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts predict that IQVIA will post 10.81 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In related news, Director John G. Danhakl purchased 1,275 shares of IQVIA stock in a transaction dated Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.60% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. UMB Bank n.a. increased its position in shares of IQVIA by 74.4% during the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company's stock worth $55,000 after purchasing an additional 99 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt increased its position in shares of IQVIA by 429.2% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,233 shares of the medical research company's stock worth $292,000 after purchasing an additional 1,000 shares during the last quarter. Exchange Traded Concepts LLC increased its position in shares of IQVIA by 2.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 4,388 shares of the medical research company's stock worth $1,040,000 after purchasing an additional 98 shares during the last quarter. Creative Planning increased its position in shares of IQVIA by 17.8% during the 3rd quarter. Creative Planning now owns 21,013 shares of the medical research company's stock worth $4,980,000 after purchasing an additional 3,176 shares during the last quarter. Finally, Swedbank AB increased its position in shares of IQVIA by 0.9% during the 3rd quarter. Swedbank AB now owns 91,489 shares of the medical research company's stock worth $21,680,000 after purchasing an additional 786 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.